Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Case report

Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient

Authors: Annick De Weerdt, Amélie Dendooven, Annemie Snoeckx, Jan Pen, Martin Lammens, Philippe G. Jorens

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

The FOLFOX regimen, i.e., folinic acid (FOL), fluorouracil (F) and oxaliplatin (OX), is a drug cocktail that is used to treat gastric and colorectal cancers. Despite the concomitant improvements in response rate, duration of response and patient survival, reports of serious toxic pulmonary side effects have progressively emerged.

Case presentation

We describe a patient who was treated with FOLFOX as an adjuvant to a rectosigmoidal resection of a rectosigmoidal carcinoma and who developed respiratory insufficiency requiring mechanical ventilation. Computed tomography (CT) imaging and open lung biopsy findings were compatible with interstitial pneumonia (IP). She received multimodal combination treatment (acetylcysteine, corticosteroids, immune globulins and cyclophosphamide) and survived.
We performed a systematic literature search and reviewed all 45 reported cases of FOLFOX-related lung toxicity and/or pulmonary fibrosis for their clinical characteristics and their outcomes related to therapy.

Conclusions

We found that for the 45 cases with available data, the median age was 70 years, and the male–female ratio was 3.5: 1. In the patients exhibiting only mild respiratory symptoms, discontinuation of the culprit drug (oxaliplatin) resulted in a 100% regression of the symptoms. However the prognosis of the respiratory insufficient patient proved to be grim: death occurred in 76.9% of the cases despite conventional treatment with corticosteroids. We therefore urge oncologists and critical care specialists not to limit their interventions to the discontinuation of chemotherapy, artificial ventilation, corticosteroids and glutathione replenishment and to consider the gradual introduction of additional immune-modulating agents whenever life-threatening respiratory symptoms in oxaliplatin-treated patients do not subside; all the more so considering the fact that our analysis showed that every patient who survived intubation and mechanical ventilation experienced a full clinical recovery.
Literature
1.
Saltz L. Systemic therapy for metastatic colorectal cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2013;11:649–52.CrossRefPubMed
2.
Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol. 2009;43:1–8.CrossRef
3.
Chen ML, Fang CH, Liang LS, Dai LH, Wang XK. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. Surg Oncol. 2010;19:38–45.CrossRefPubMed
4.
Gagnadoux F, Roiron C, Carrie E, Monnier-Cholley L, Lebeau B. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. Am J Clin Oncol. 2002;25:388–90.CrossRefPubMed
5.
Hannan LM, Yoong J, Chong G, McDonald CF. Interstitial lung disease in a patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for metastatic colorectal cancer. Radiol Oncol. 2012;46:360–2.CrossRefPubMedPubMedCentral
6.
Lim JH, Kim H, Choi WG, Lee MH. Interstitial lung disease associated with FOLFOX chemotherapy. J Cancer Res Ther. 2010;6:546–8.CrossRefPubMed
7.
Muneoka K, Shirai Y, Sasaki M, Wakai T, Sakata J, Hatakeyama K. Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX). Int J Clin Oncol. 2009;14:457–9.CrossRefPubMed
8.
9.
Pena Alvarez C, Suh Oh HJ, Saenz de Miera Rodriguez A, Garcia Arroyo FR, Covela Rua M, Salgado Boquete L, et al. Interstitial lung disease associated with oxaliplatin: description of two cases. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2009;11:332–3.CrossRef
10.
Arevalo Lobera S, Sagastibeltza Marinelarena N, Elejoste Echeberria I, Mele Olive M, Egana Otano L, Basterretxea Badiola L, et al. Fatal pneumonitis induced by oxaliplatin. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2008;10:764–7.CrossRef
11.
Jung KH, Kil SY, Choi IK, Seo JH, Shin C, Kim YS, et al. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX). Int J Tuberc Lung Dis. 2006;10:1181–2.PubMed
12.
Prochilo T, Abeni C, Bertocchi P, Zaniboni A. Oxaliplatin-induced lung toxicity. Case report and review of the literature. Curr Drug Saf. 2012;7:179–82.CrossRefPubMed
13.
Shogbon AO, Hap J, Dretler R, Dalvi AG. Cryptogenic organizing pneumonia during adjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX) for colon cancer. J Pharm Pract. 2013;26:62–6.CrossRefPubMed
14.
Wildner D, Boxberger F, Wein A, Wolff K, Albrecht H, Mannlein G, et al. Granulomatous lung disease requiring mechanical ventilation induced by a single application of oxaliplatin-based chemotherapy for colorectal cancer: a case report. Case reports in oncological medicine. 2013;2013:683948.CrossRefPubMedPubMedCentral
15.
Shimura T, Fuse N, Yoshino T, Minashi K, Tahara M, Doi T, et al. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Ann Oncol 2010;21:2005-10.
16.
Dahlqvist C, Fremault A, Carrasco J, Colinet B. Obliterative bronchiolitis with organising pneumonia following FOLFOX 4 chemotherapy. Rev Mal Respir. 2010;27:84–7.CrossRefPubMed
17.
Garrido M, O'Brien A, Gonzalez S, Clavero JM, Orellana E. Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report. Chest. 2007;132:1997–9.CrossRefPubMed
18.
Homma T, Kurokawa M, Yamamoto Y, Matsukura S, Ieki K, Suzuki S, et al. Oxaliplatin-induced lung injury with allergic reaction. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2011;23:232–5.CrossRefPubMedPubMedCentral
19.
Ohori H, Takahashi M, Ogasawara N, Suzuki M, Miyate Y, Kato S. Two cases of interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX). Gan To Kagaku Ryoho. 2009;36:295–8.PubMed
20.
Meyer KC. The role of bronchoalveolar lavage in interstitial lung disease. Clin Chest Med. 2004;25:637–49. vCrossRefPubMed
21.
22.
Krause I, Shoenfeld Y. Intravenous immunoglobulin treatment for fibrosis, atherosclerosis, and malignant conditions. Methods in molecular medicine. 2005;109:403–8.PubMed
23.
Molina V, Blank M, Shoenfeld Y. Intravenous immunoglobulin and fibrosis. Clin Rev Allergy Immunol. 2005;29:321–6.CrossRefPubMed
24.
Molina V, Haj-Yahia S, Solodeev I, Levy Y, Blank M, Shoenfeld Y. Immunomodulation of experimental pulmonary fibrosis by intravenous immunoglobulin (IVIG). Autoimmunity. 2006;39:711–7.CrossRefPubMed
25.
Basyigit I, Onyilmaz TA, Boyaci H, Temiz S, Inan N, Baris SA, et al. Interstitial pneumonitis associated with FOLFOX-6 chemotherapy. Translational Medicine. 2014;4
26.
Choi JH, Shin JA, Park HK, Kim SY, Jung H, Lee SS, et al. Sarcoidosis associated with oxaliplatin-based chemotherapy for colorectal cancer. Case reports in oncological medicine. 2014;2014:203027.CrossRefPubMedPubMedCentral
27.
Ishizone S, Koide N, Akita N, Karasawa F, Kobayashi N, Koizumi T, et al. Fatal interstitial pneumonia associated with oxaliplatin-based therapy in a patient with metastatic rectal cancer. Clin J Gastroenterol. 2011;4:157–61.CrossRefPubMed
28.
Lee EJ, Lee SY, In KH, Kim CH, Park S. Organizing pneumonia associated with oxaliplatin-combined chemotherapy: a case report. Med Princ Pract. 2012;21:89–92.CrossRefPubMed
29.
Mundt P, Mochmann HC, Ebhardt H, Zeitz M, Duchmann R, Pauschinger M. Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer. Oncology. 2007;73:270–2.CrossRefPubMed
30.
Park S, Jung JJ, Kim GB, Yoon HS, Ko SH, Ko JE, et al. Interstitial lung disease associated with combination chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin. Korean J Gastroenterol. 2010;55:340–3.CrossRefPubMed
31.
Piccolo D, Feeney KT, Tribe AE, Thompson PJ, Millward MJ, van Hazel GA. Oxaliplatin-induced interstitial lung disease. Asia-Pacific Journal of Clinical Oncology. 2008;4:175–80.CrossRef
32.
Pontes LB, Armentano DP, Soares A, Gansl RC. Fatal pneumonitis induced by oxaliplatin: description of three cases. Case reports in oncology. 2012;5:104–9.CrossRefPubMedPubMedCentral
33.
Ruiz-Casado A, Garcia MD, Racionero MA. Pulmonary toxicity of 5-fluoracil and oxaliplatin. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2006;8:624.CrossRef
34.
Ryu CG, Jung EJ, Kim G, Kim SR, Hwang DY. Oxaliplatin-induced Pulmonary Fibrosis: Two Case Reports. Journal of the Korean Society of Coloproctology. 2011;27:266–9.CrossRefPubMedPubMedCentral
35.
36.
Trisolini R, Lazzari Agli L, Tassinari D, Rondelli D, Cancellieri A, Patelli M, et al. Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy. Eur Respir J. 2001;18:243–5.PubMed
37.
Watkins J, Slade JH, Phan A, Eng C, Weissferdt A, Overman MJ. Fatal diffuse alveolar damage associated with oxaliplatin administration. Clin Colorectal Cancer. 2011;10:198–202.PubMed
38.
Wilcox BE, Ryu JH, Kalra S. Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: a report of three cases. Respir Med. 2008;102:273–9.CrossRefPubMed
39.
Yague XH, Soy E, Merino BQ, Puig J, Fabregat MB, Colomer R. Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2005;7:515–7.CrossRef
40.
Abotchie PN, Vernon SW, Du XL. Gender differences in colorectal cancer incidence in the United States, 1975-2006. J Women's Health (Larchmt). 2012;21:393–400.CrossRef
41.
Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467–77.CrossRefPubMed
42.
Wu CY, Lin JT. The changing epidemiology of Asian digestive cancers: From etiologies and incidences to preventive strategies. Best Pract Res Clin Gastroenterol. 2015;29:843–53.CrossRefPubMed
43.
Wiela-Hojenska A, Kowalska T, Filipczyk-Cisarz E, Lapinski L, Nartowski K. Evaluation of the toxicity of anticancer chemotherapy in patients with colon cancer. Adv Clin Exp Med. 2015;24:103–11.CrossRefPubMed
44.
Schmetzer O, Florcken A. Sex differences in the drug therapy for oncologic diseases. Handb Exp Pharmacol. 2012:411–42.
45.
Ferguson EC, Berkowitz EA. Lung CT: Part 2, The interstitial pneumonias--clinical, histologic, and CT manifestations. AJR Am J Roentgenol. 2012;199:W464–76.CrossRefPubMed
46.
Ryu JH, Daniels CE, Hartman TE, Yi ES. Diagnosis of interstitial lung diseases. Mayo Clin Proc. 2007;82:976–86.CrossRefPubMed
47.
Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration; international review of thoracic diseases. 2004;71:301–26.CrossRefPubMed
48.
Alter P, Herzum M, Soufi M, Schaefer JR, Maisch B. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem. 2006;4:1–5.CrossRefPubMed
49.
Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993;53:3028–33.PubMed
50.
Andou H, Itoh K, Tsuda T. A case of fluorouracil-induced pneumonitis. Nihon Kyobu Shikkan Gakkai Zasshi. 1997;35:1080–3.PubMed
51.
Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002;1:227–35.PubMed
52.
Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053–71.CrossRefPubMed
53.
Vietor NO, George BJ. Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent. J Oncol Pharm Pract. 2012;18:355–9.CrossRefPubMed
54.
Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol. 2000;94:99–104.CrossRefPubMed
55.
Fouque A, Debure L, Legembre P. The CD95/CD95L signaling pathway: a role in carcinogenesis. Biochim Biophys Acta. 1846;2014:130–41.
56.
Ge Y, Peng Q, Zhang S, Zhou H, Lu X, Wang G. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol. 2015;34:99–105.CrossRefPubMed
57.
Burz C, Berindan-Neagoe IB, Balacescu O, Tanaselia C, Ursu M, Gog A, et al. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. Journal of gastrointestinal and liver diseases : JGLD. 2009;18:39–43.PubMed
Metadata
Title
Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient
Authors
Annick De Weerdt
Amélie Dendooven
Annemie Snoeckx
Jan Pen
Martin Lammens
Philippe G. Jorens
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3576-y

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

Receiver operating characteristic analysis of prediction for gastric cancer development using serum pepsinogen and Helicobacter pylori antibody tests

Research article

Isolation and characterization of a new naturally immortalized human breast carcinoma cell line, KAIMRC1

Research article

miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway

Research article

Overexpression of Cullin7 is associated with hepatocellular carcinoma progression and pathogenesis

Research article

Microparticles shed from multidrug resistant breast cancer cells provide a parallel survival pathway through immune evasion

Research article

Robot-assisted radical prostatectomy significantly reduced biochemical recurrence compared to retro pubic radical prostatectomy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits